{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 42,
        "end": 49
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 115,
        "end": 139
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 187,
        "end": 196
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 220,
        "end": 229
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 252,
        "end": 270
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 67,
        "end": 90
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 93,
        "end": 98
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 142,
        "end": 145
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "24611967_4",
  "text": "METHODS : Fifty-two patients with fasting glucose 100-240 mg/dL or glycosylated hemoglobin ( HbA1c ) > = 6.0 % and alanine aminotransferase ( ALT ) 40-250 IU/L were randomized to receive metformin ( 250 mg t.i.d. ) , or metformin ( 250 mg t.i.d. ) and carnitine -orotate complex ( 300 mg t.i.d. ) for 12 weeks ( n = 26 per group ) ."
}
